Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Stock Information for Vor Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vor Biopharma Inc.

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
Vor Bio Announces $55.6 Million Private Placement
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.